A Phase 1b Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Erlotinib or Alectinib in Patients With Advanced Non-Small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 12 Nov 2019 Planned End Date changed from 30 Sep 2019 to 31 Dec 2019.
- 12 Nov 2019 Planned primary completion date changed from 30 Sep 2019 to 31 Dec 2019.
- 27 Feb 2019 Planned End Date changed from 18 Jan 2019 to 30 Sep 2019.